Literature DB >> 28213675

[Adherence in specific immunotherapy].

M-L Lemberg1, M-J Joisten1, R Mösges2.   

Abstract

Allergies are steadily gaining in importance in the Western world. For over one hundred years, immunology has been the only causal treatment. Specific immunotherapy (SIT) aims at the cure of allergy or at least freedom from allergy symptoms. In association with this, adherence poses a complex problem. Both treatment applications commonly used in Germany-sublingual and subcutaneous immunotherapy-show poor persistence on the part of the patients. In most cases, SIT is not carried out to the end of the recommended duration and instead is discontinued prematurely. Corresponding figures from 3‑year studies in the literature range from 41- 93% for uncompleted SLIT and from 40-77% for uncompleted SCIT. Patient adherence is subject to influencing factors of various dimensions that are interdependent in complex relationships. The physician-patient relationship is just as decisive a factor for treatment success as the patient's understanding of allergy, treatment, and the importance of adherence.

Entities:  

Keywords:  Allergies; Compliance; Persistence; Subcutaneous; Sublingual

Mesh:

Substances:

Year:  2017        PMID: 28213675     DOI: 10.1007/s00105-017-3946-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  29 in total

1.  Compliance, concordance, adherence.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-04       Impact factor: 4.335

2.  Adherence to sublingual immunotherapy in preschool children.

Authors:  Giovanni B Pajno; Lucia Caminiti; Giuseppe Crisafulli; Salvatore Barberi; Massimo Landi; Tommaso Aversa; Mariella Valenzise; Giovanni Passalacqua
Journal:  Pediatr Allergy Immunol       Date:  2012-09-18       Impact factor: 6.377

Review 3.  Adherence to Sublingual Immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Gualtiero Leo; Erminia Ridolo
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

4.  A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy.

Authors:  Nicole M Hsu; William R Reisacher
Journal:  Int Forum Allergy Rhinol       Date:  2012-03-20       Impact factor: 3.858

5.  Patient dropouts before completion of optimal dose, multiple allergen immunotherapy.

Authors:  B J Rhodes
Journal:  Ann Allergy Asthma Immunol       Date:  1999-03       Impact factor: 6.347

Review 6.  Solving the Problem of Nonadherence to Immunotherapy.

Authors:  Bruce G Bender; Richard F Lockey
Journal:  Immunol Allergy Clin North Am       Date:  2016-02       Impact factor: 3.479

7.  Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis.

Authors:  Cheryl S Hankin; Linda Cox; Amy Bronstone; Zhaohui Wang
Journal:  J Allergy Clin Immunol       Date:  2013-01-30       Impact factor: 10.793

Review 8.  Long-term adherence to sublingual therapy: literature review and suggestions for management strategies based on patients' needs and preferences.

Authors:  A Antico
Journal:  Clin Exp Allergy       Date:  2014-11       Impact factor: 5.018

9.  The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey.

Authors:  Moises A Calderon; Linda Cox; Thomas B Casale; Ralph Mösges; Oliver Pfaar; Hans-Jørgen Malling; Joaquin Sastre; Musa Khaitov; Pascal Demoly
Journal:  Allergy Asthma Clin Immunol       Date:  2015-05-22       Impact factor: 3.406

10.  Patient's compliance with allergen immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Erminia Ridolo; Paola Puccinelli; Massimiliano Liuzzo; Silvia Scurati; Franco Frati
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more
  1 in total

1.  Resveratrol Treatment Prevents Increase of Mast Cells in Both Murine OVA Enteritis and IL-10-/- Colitis.

Authors:  Sabrina Bilotta; Julian Arbogast; Nadine Schart; Maurice Frei; Axel Lorentz
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.